ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona

Vall d'Hebron Institute of Oncology (VHIO) at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Vall d'Hebron Institute of Oncology (VHIO) takes part in 29 sessions at ESMO 2026 in Madrid. Its program spans cancer biomarkers and treatment across several tumour types. Topics include tracking tumour DNA over time, identifying genomic changes as cancer progresses, and matching therapies to findings such as HER2 expression.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Translational cancer research institute on the campus of Vall d'Hebron University Hospital in Barcelona, Spain, running early-phase trials.
Poster
Fri Oct 23
13:00–15:00
Poster
Fri Oct 23
13:00–15:00
Functional and quantitative characterization of KRAS-associated variants of uncertain significance in pancreatic cancer
ePoster session 17
Gastrointestinal cancersBiomarkers & precision oncology
Poster
Fri Oct 23
13:00–15:00
Talk
Fri Oct 23
13:30
AI and digital health
YO Mentorship session · with Krankenhaus Nordwest
Chair
Fri Oct 23
13:30–14:45
Invasive lobular carcinoma: Detecting and managing an elusive enemy
with Institut Jules Bordet
Breast cancer
Talk
Fri Oct 23
13:50–14:05
Medical oncology perspective
Invasive lobular carcinoma: Detecting and managing an elusive enemy
Breast cancer
Poster
Fri Oct 23
15:15–16:00
A pan-cancer analysis of serial biopsies for emerging ESCAT I alterations at disease progression
Friday Poster Display session 3
Gastrointestinal cancersLung & thoracic cancersBreast cancer
Poster
Fri Oct 23
15:15–16:00
Beyond HER2 IHC: ERBB2 RNA-ISH stratifies benefit from T-DXd combinations
Friday Poster Display session 3
Gastrointestinal cancersBreast cancerBiomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Poster
Fri Oct 23
15:15–16:00
Longitudinal ctDNA monitoring and radiological response to targeted therapies (TT) in early-phase clinical trials (EPCT)
Friday Poster Display session 6
Biomarkers & precision oncology
Poster
Fri Oct 23
15:15–16:00
Real-world outcomes of larotrectinib in solid tumors with tropomyosin receptor kinase fusion (GETNE S2411 / SPAINTRK)
Friday Poster Display session 6
Sarcoma, CNS, head & neck and rare cancersLung & thoracic cancersBreast cancer
Chair
Fri Oct 23
16:15–17:45
Raising the bar for tumor-agnostic studies
with Netherlands Cancer Institute
Biomarkers & precision oncology
Chair
Fri Oct 23
16:15–17:45
The evolving standards in the management of chronic lymphocytic leukemia
with Ulm University
Haematological malignancies
Talk
Fri Oct 23
17:15–17:35
From hematologic success to solid tumor challenges: CAR-T therapy and T-cell transformation risk
The evolving standards in the management of chronic lymphocytic leukemia
Haematological malignancies
Chair
Sat Oct 24
08:30–10:00
Metastases: Understanding and targeting cancer spread
with The Christie
Biomarkers & precision oncology
Talk
Sat Oct 24
08:30–08:50
Understanding the genomic landscape of metastatic cancer and its therapeutic potential
Metastases: Understanding and targeting cancer spread
Biomarkers & precision oncology
Poster
Sat Oct 24
12:00–12:45
An investigator-initiated first-in-human phase I study of autologous p95HER2.CAR-TECH2Me T cells in patients with HER2-positive advanced solid tumors: CATHERINE
Saturday Poster Display session 4
Gastrointestinal cancersGynaecological cancersBreast cancer
Poster
Sat Oct 24
12:00–12:45
Clinical and molecular characterization of MTAP/CDKN2A/B-loss glioblastoma in an NGS-profiled institutional cohort
Saturday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Sat Oct 24
12:00–12:45
Clinical and molecular landscape of CDK4-Amplified IDH-wildtype glioblastoma in a real-world multicentric cohort
Saturday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology
Poster
Sat Oct 24
12:00–12:45
Clinical utility of itRECIST assessment to refine patient and injected lesion selection in human intratumoral immunotherapy (HIT-IT) trials in solid tumors
Saturday Poster Display session 3
Gastrointestinal cancersMelanoma & skin cancersSarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Poster
Sat Oct 24
12:00–12:45
Second-line treatment of glioblastoma in real-world practice: A multicentric cohort analysis
Saturday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancers
Poster
Sat Oct 24
12:00–12:45
Spatial single-cell profiling of tumor phenotypic remodeling and immune engagement during HER2 blockade in HER2-positive breast cancer
Saturday Poster Display session 2
Breast cancerBiomarkers & precision oncology
Poster
Sat Oct 24
12:00–12:45
Tuvusertib in recurrent IDH and ATRX mutant astrocytoma: Design of the phase 2 GEINO-2401 / TUVASTRAT study
Saturday Poster Display session 3
Sarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
19:23–19:58
Navigating the NET treatment journey
Ipsen - Treatment decisions that shape the journey in RCC and NETs · with University Hospital Erlangen
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Talk
Sun Oct 25
08:35–08:55
AI in the tumour board
Using Large Language Models (LLM) in multidisciplinary tumor boards: Practical applications and considerations
Talk
Sun Oct 25
10:15–10:30
Clinical trial design in developmental therapeutics
Emerging concepts in developmental therapeutics
Talk
Sun Oct 25
11:00–11:15
Advanced/metastatic prostate cancer: Case presentation
ESMO Clinical Practice Guidelines 2
Breast cancerGenitourinary cancers
Poster
Sun Oct 25
12:00–12:45
Microbial interactions signatures as non-invasive tool for early CRC detection
Sunday Poster Display session 2
Gastrointestinal cancersBiomarkers & precision oncology
Chair
Sun Oct 25
14:45–16:15
Toxicities of immunotherapies beyond immune checkpoints
with Copenhagen University Hospital – Herlev
Nursing & supportive care
Talk
Sun Oct 25
15:05–15:25
Current landscape of the use of radioligands in gastroenteropancreatic Neuroendocrine neoplasms
Radioligand therapy: A game-changer in the treatment sequence of advanced neuroendocrine tumors
Sarcoma, CNS, head & neck and rare cancers
Talk
Sun Oct 25
15:15–15:30
Chair
Mon Oct 26
08:30–10:00
Rapid oral: Sarcoma
with Memorial Sloan Kettering Cancer Center, Istituto Ortopedico Rizzoli
Sarcoma, CNS, head & neck and rare cancers
Abstract
Mon Oct 26
09:12–09:24
Invited Discussant 3720RO, 3721RO and 3722RO
Rapid oral: Sarcoma
Sarcoma, CNS, head & neck and rare cancers
Chair
Mon Oct 26
10:15–11:45
Talk
Mon Oct 26
15:15–15:30
How can we extrapolate data from phase III done exclusively in China? Strategies for global access
ESMO-CSCO: Navigating the development pathways of cancer therapeutics -From China to the world

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Vall d'Hebron Institute of Oncology (VHIO)

Tell us what you sell and we’ll find the people at Vall d'Hebron Institute of Oncology (VHIO) most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction